Fontan-associated liver disease and total cavopulmonary anatomical flow effectors.


Journal

Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 11 03 2021
accepted: 24 03 2021
pubmed: 10 4 2021
medline: 11 6 2021
entrez: 9 4 2021
Statut: ppublish

Résumé

We investigated a relationship between a composite index comprised of Fontan-circuit anatomical features and hepatic fibrosis scores from biopsy. We identified living extracardiac Fontan patients, ≥7 years old and ≥5 but <20 years postoperative, that underwent cardiac catheterization and transvenous liver biopsy between March 2012 and September 2020. We divided patients into anatomical groups and applied a risk score to each patient. We compared average anatomical risk scores with average hepatic total fibrosis scores by group. We identified 111 patients that met inclusion criteria. After excluding four patients, we assigned 107 to one of 12 anatomical variant groups (n ≥ 3). For the 107, the average age at liver biopsy was 14 ± 6 years old. Of the 107, 105 (98%) were New York Heart Association Class 1. We found average anatomical risk scores by group correlated with average total fibrosis scores by group (R = 0.8; p = .005). An average Fontan duration to biopsy of 10 ± 1 years was similar for all 12 anatomical groups. We found no other clinical variables, laboratory, or hemodynamic values that trended with anatomical risk scores or hepatic total fibrosis scores. In a cohort of relatively young, stable extracardiac Fontan patients, average composite anatomical risk scores strongly correlated with average hepatic total fibrosis scores by anatomical group. These findings suggest that some anatomical variants in extracardiac Fontan patients are associated with higher Fontan-associated liver disease (FALD)-related hepatic total fibrosis scores than others, despite similar Fontan durations.

Identifiants

pubmed: 33834526
doi: 10.1111/jocs.15553
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2329-2335

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Rychik J, Atz AM, Celermajer DS, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019:CIR0000000000000696. https://doi.org/10.1161/CIR.0000000000000696
Gordon-Walker TT, Bove K, Veldtman G. Fontan-associated liver disease: a review. J Cardiol. 2019;74:223-232.
Wu FM, Ukomadu C, Odze RD, Valente AM, Mayer Jr. JE, Earing MG. Liver disease in the patient with Fontan circulation. Congenit Heart Dis. 2011;6:190-201.
Surrey LF, Russo P, Rychik J, et al. Prevalence and characterization of fibrosis in surveillance liver biopsies of patients with Fontan circulation. Hum Pathol. 2016;57:106-115.
Hilscher MB, Johnson JN, Cetta F, et al. Surveillance for liver complications after the Fontan procedure. Congenit Heart Dis. 2017;12:1-10.
Rodríguez de Santiago E, Téllez L, Garrido-Lestache Rodríguez-Monte E, et al. Fontan protein-losing enteropathy is associated with advanced liver disease and a proinflammatory intestinal and systemic state. Liver Int. 2020;40:638-645.
Maida M, Macaluso FS, Salomone F, Petta S. Non-invasive assessment of liver injury in non-alcoholic fatty liver disease: a review of literature. Curr Mol Med. 2016;16:721-737.
Zhuang Y, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two-dimensional shear-wave elastography performance in the noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B: comparison with serum fibrosis indexes. Radiology. 2017;283:873-882.
Chindamo MC, Boursier J, Luiz RR, et al. Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C. World J Hepatol. 2017;9:310-317.
Stasi C, Salomoni E, Arena U, et al. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: a preliminary study. Eur J Pharmacol. 2017;806:105-109.
Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152:1544-1577.
Evans WN, Acherman RJ, Ciccolo ML, et al. A composite noninvasive index correlates with liver fibrosis scores in post-Fontan patients: preliminary findings. Congenit Heart Dis. 2018;13:38-45.
Evans WN, Acherman RJ, Mayman GA, et al. The rate of hepatic fibrosis progression in patients post-Fontan. Pediatr Cardiol. 2020;41:905-909. https://doi.org/10.1007/s00246-020-02331-0
Evans WN, Acherman RJ, Reardon LC, et al. Fontan outcomes and pulmonary blood flow at birth. Pediatr Cardiol. 2016;37:30-36.
Evans WN, Acherman RJ, Mayman GA, et al. Fontan venovenous collaterals and hepatic fibrosis. J Card Surg. 2020;35:2974-2978. https://doi.org/10.1111/jocs.14951
Evans WN, Acherman RJ, Mayman GA, et al. Fontan-associated anatomical variants and hepatic fibrosis. World J Pediatr Congenit Heart Surg. 2021;12(2):168-172.
Atton G, Gordon K, Brice G, et al. The lymphatic phenotype in Turner syndrome: an evaluation of nineteen patients and literature review. Eur J Hum Genet. 2015;23:1634-1639.
Trout AT, Sheridan RM, Serai SD, et al. Diagnostic performance of MR elastography for liver fibrosis in children and young adults with a spectrum of liver diseases. Radiology. 2018;287:824-832.
Srinivasan A, Guzman AK, Rand EB, et al. Percutaneous liver biopsy in Fontan patients. Pediatr Radiol. 2019;49:342-350.
Silva-Sepulveda JA, Fonseca Y, Vodkin I, et al. Evaluation of Fontan liver disease: correlation of transjugular liver biopsy with magnetic resonance and hemodynamics. Congenit Heart Dis. 2019;14:600-608.
Rathgeber SL, Guttman OR, Lee AF, et al. Fontan-associated liver disease: spectrum of disease in children and adolescents. J Am Heart Assoc. 2020;9:e012529. https://doi.org/10.1161/JAHA.119.012529
Dohan A, Guerrache Y, Boudiaf M, Gavini JP, Kaci R, Soyer P. Transjugular liver biopsy: indications, technique and results. Diagn Interv Imaging. 2014;95:11-15.
Vaikunth SS, Higgins JP, Concepcion W, et al. Does liver biopsy accurately measure fibrosis in Fontan-associated liver disease? A comparison of liver biopsy pre-combined heart and liver transplant and liver explant post-transplant. Clin Transplant. 2020;34:e14120. https://doi.org/10.1111/ctr.14120
Schwartz MC, Sullivan LM, Glatz AC, et al. Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery. Pediatr Cardiol. 2013;34:135-142.
Evans WN, Winn BJ, Yumiaco NS, et al. Transvenous hepatic biopsy in stable Fontan patients undergoing cardiac catheterization. Pediatr Cardiol. 2014;35:1273-1278.
Chen YC, Weng KP, Chien KJ, et al. Hepatic pathology in patients after Fontan operation: a computed tomography imaging study. J Chin Med Assoc. 2019;82:856-860.
Sharma VJ, Iyengar AJ, Zannino D, et al. Protein-losing enteropathy and plastic bronchitis after the Fontan procedure. J Thorac Cardiovasc Surg. 2020;S0022-5223(20):32359-3235. https://doi.org/10.1016/j.jtcvs.2020.07.107
Moon J, Shen L, Likosky DS, et al. Relationship of ventricular morphology and atrioventricular valve function to long-term outcomes following Fontan procedures. J Am Coll Cardiol. 2020;76:419-431.
Oka N, Miyamoto T, Tomoyasu T, Hayashi H, Miyaji K. Risk factors for mid-term liver disease after the Fontan procedure. Int Heart J. 2020;61:979-983.
McHugo S, Nolke L, Delassus P, MacCarthy E, Morris L, McMahon CJ. An in-vitro evaluation of the flow haemodynamic performance of Gore-Tex extracardiac conduits for univentricular circulation. J Cardiothorac Surg. 2020;15(1):235. https://doi.org/10.1186/s13019-020-01269-x
Gewillig M, Brown SC. The Fontan circulation after 45 years: update in physiology. Heart. 2016;102:1081-1086.
Alsaied T, Moore RA, Lang SM, et al. Myocardial fibrosis, diastolic dysfunction and elevated liver stiffness in the Fontan circulation. Open Heart. 2020;7(2):e001434. https://doi.org/10.1136/openhrt-2020-001434
Ascuitto RJ, Kydon DW, Ross-Ascuitto NT. Pressure loss from flow energy dissipation: relevance to Fontan-type modifications. Pediatr Cardiol. 2001;22:110-115.
Kotani Y, Zhu J, Grosse-Wortmann L, et al. Anatomical risk factors, surgical treatment, and clinical outcomes of left-sided pulmonary vein obstruction in single-ventricle patients. J Thorac Cardiovasc Surg. 2015;149:1332-1338.
Trusty PM, Wei ZA, Rychik J, et al. Cardiac magnetic resonance-derived metrics are predictive of liver fibrosis in Fontan patients. Ann Thorac Surg. 2020;109:1904-1911.
Maeda K, Yamaki S, Kado H, Asou T, Murakami A, Takamoto S. Hypoplasia of the small pulmonary arteries in hypoplastic left heart syndrome with restrictive atrial septal defect. Circulation. 2004;110(11 suppl 1):II139-II146.
Poterucha JT, Johnson JN, Taggart NW, et al. Embolization of veno- venous collaterals after the Fontan operation is associated with decreased survival. Congenit Heart Dis. 2015;10(5):E230-E236.
Kodama Y, Ishikawa Y, Kuraoka A, et al. Systemic-to-pulmonary collateral flow correlates with clinical condition late after the Fontan procedure. Pediatr Cardiol. 2020;41:1800-1806.
Cattaruzza M, Wagner AH, Hecker M. Mechanosensitive pro-inflammatory gene expression in vascular cells. In: Kamkin A, Kiseleva I, eds. Mechanical Stretch and Cytokines. Mechanosensitivity in Cells and Tissues. Vol 5. Dordrecht: Springer; 2012. https://doi.org/10.1007/978-94-007-2004-6_3
Hinz B. The extracellular matrix and transforming growth factor-β1: tale of a strained relationship. Matrix Biol. 2015;47:54-65.
Rychik J, Goldmuntz E. Invited commentary: the hunt for mechanistic origins of liver fibrosis in the Fontan circulation. World J Pediatr Congenit Heart Surg. 2021;12:173-175.
Schleiger A, Kramer P, Salzmann M, et al. Evaluation of Fontan failure by classifying the severity of Fontan-associated liver disease: a single-centre cross-sectional study. Eur J Cardiothorac Surg. 2020:ezaa310. https://doi.org/10.1093/ejcts/ezaa310
Book WM, Gerardin J, Saraf A, Marie Valente A, Rodriguez F, 3rd. Clinical phenotypes of Fontan failure: implications for management. Congenit Heart Dis. 2016;11:296-308.
Ohuchi H. Adult patients with Fontan circulation: what we know and how to manage adults with Fontan circulation? J Cardiol. 2016;68:181-189.
Haworth SG, Reid L. Quantitative structural study of pulmonary circulation in the newborn with pulmonary atresia. Thorax. 1977;32:129-133.

Auteurs

William N Evans (WN)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.
Department of Pediatrics, School of Medicine, Division of Pediatric Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Ruben J Acherman (RJ)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.
Department of Pediatrics, School of Medicine, Division of Pediatric Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Alvaro Galindo (A)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.
Department of Pediatrics, School of Medicine, Division of Pediatric Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Abraham Rothman (A)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.
Department of Pediatrics, School of Medicine, Division of Pediatric Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Michael L Ciccolo (ML)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.
Department of Surgery, School of Medicine, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Juan Lehoux (J)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.

Brody J Winn (BJ)

Laboratory Medicine Consultants, Las Vegas, Nevada, USA.

Noel S Yumiaco (NS)

Laboratory Medicine Consultants, Las Vegas, Nevada, USA.

Humberto Restrepo (H)

Children's Heart Center Nevada, Las Vegas, Nevada, USA.
Department of Pediatrics, School of Medicine, Division of Pediatric Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH